Phaarmasia

{
  "main_header": {
    "sid": 306122,
    "name": "Phaarmasia",
    "stock_name": "Phaarmasia",
    "full_name": "Phaarmasia Ltd",
    "name_url": "stocks-analysis/phaarmasia",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "92.98",
    "chg": 4.3,
    "chgp": "4.85%",
    "dir": 1,
    "prev_price": "88.68",
    "mcapval": "61.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 523620,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE486I01016",
    "curr_date": "Jul 17, 03:30 PM",
    "curr_time": "10:23 AM",
    "last_traded_at": "Jul 17, 03:30 PM IST",
    "bse_nse_vol": "424 ",
    "exc_status": "Active",
    "traded_date": "Jul 17, 2026",
    "traded_date_str": "2026 07 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/phaarmasia-306122-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Phaarmasia Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-downgraded-to-sell-amid-mixed-fundamentals-and-technical-signals-4103064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/PhaarmasiaLtd_mojoScore_4103064.png",
        "date": "2026-07-15 08:02:39",
        "description": "Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 14 July 2026. This shift reflects a complex interplay of deteriorating technical indicators, flat financial performance, and weak long-term fundamentals despite some attractive valuation metrics. The company’s Mojo Score has declined to 44.0, signalling caution for investors amid volatile price action and operational challenges."
      },
      {
        "title": "Phaarmasia Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-upgraded-to-hold-as-technicals-improve-amid-mixed-financials-4095707",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/PhaarmasiaLtd_mojoScore_4095707.png",
        "date": "2026-07-10 08:02:02",
        "description": "Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 9 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends despite recent flat quarterly results and ongoing operational challenges."
      },
      {
        "title": "Phaarmasia Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-sell-by-marketsmojo-4093387",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/PhaarmasiaLtd_mojoScore_4093387.png",
        "date": "2026-07-08 10:11:28",
        "description": "Phaarmasia Ltd is rated Sell by MarketsMOJO, with this rating last updated on 11 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 July 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Phaarmasia Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-sell-by-marketsmojo-4072974",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PhaarmasiaLtd_mojoScore_4072974.png",
        "date": "2026-06-25 10:11:35",
        "description": "Phaarmasia Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with the most recent and relevant data to assess the company’s outlook."
      },
      {
        "title": "Phaarmasia Ltd Downgraded to Sell Amid Mixed Technicals and Weak Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-downgraded-to-sell-amid-mixed-technicals-and-weak-financials-4048276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PhaarmasiaLtd_mojoScore_4048276.png",
        "date": "2026-06-12 08:02:03",
        "description": "Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a complex interplay of deteriorating technical indicators, flat financial performance, and valuation considerations, despite the company’s impressive long-term returns and attractive price-to-book ratio."
      },
      {
        "title": "Phaarmasia Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-upgraded-to-hold-by-marketsmojo-amid-mixed-financial-signals-4040263",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PhaarmasiaLtd_mojoScore_4040263.png",
        "date": "2026-06-09 08:04:57",
        "description": "Phaarmasia Ltd has seen its investment rating upgraded from Sell to Hold as of 8 June 2026, reflecting a nuanced shift in its overall outlook. This change is driven by a combination of factors including improved valuation metrics, stable quality indicators, mixed financial trends, and evolving technical signals. Despite recent flat quarterly performance and operational challenges, the stock’s long-term returns and relative valuation have prompted a reassessment of its market stance."
      },
      {
        "title": "Phaarmasia Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Mixed Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phaarmasia-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-mixed-returns-4029113",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PhaarmasiaLtd_valuationdot_4029113.png",
        "date": "2026-06-02 08:01:11",
        "description": "Phaarmasia Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the company’s valuation metrics suggest a more compelling price entry point relative to its historical averages and peer group, warranting a closer examination for investors seeking micro-cap opportunities in Pharmaceuticals & Biotechnology."
      },
      {
        "title": "Phaarmasia Ltd Q4 FY26: Quarterly Loss Amid Revenue Volatility Raises Sustainability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/phaarmasia-ltd-q4-fy26-quarterly-loss-amid-revenue-volatility-raises-sustainability-concerns-4024490",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Phaarmasia_quaterlyResult_4024490.png",
        "date": "2026-05-30 23:47:48",
        "description": "Phaarmasia Limited (NSE: PHAARMASIA, BSE: 523620), a micro-cap pharmaceutical manufacturer specialising in hormonal contraceptive tablets, reported a troubling quarter-on-quarter deterioration in Q4 FY26, posting a net loss of ₹0.70 crores against a profit of ₹16.27 crores in the previous quarter. The Hyderabad-based company, with a modest market capitalisation of ₹53.00 crores, saw its net sales plummet 51.84% sequentially to ₹7.73 crores, raising serious questions about revenue sustainability and operational stability."
      },
      {
        "title": "Phaarmasia Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-hold-by-marketsmojo-4019930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PhaarmasiaLtd_mojoScore_4019930.png",
        "date": "2026-05-29 10:10:42",
        "description": "Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. While the rating was revised earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 29 May 2026, providing investors with an up-to-date view of the company’s position in the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 734,
    "sid": "306122",
    "stock_news_url": "https://www.marketsmojo.com/news/phaarmasia-306122"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "16-Jul-2026",
      "details": "Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended June 30th 2026",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Jun-2026",
      "details": "Closure of Trading window under Reg 30 of SEBI (LODR) Reg 2015 for the Quarter ended June 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Clarification Sought From Phaarmasia Ltd On Price Movement",
      "datetime": "13-Jun-2026",
      "details": "The exchange has sought clarification from Phaarmasia Ltd on 10th June 2026 with reference to significant movement in price in order to ensure that investors have the latest relevant information about the company and to inform the market so that the interests of the investors are safeguarded.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Phaarmasia Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Signals

2026-07-15 08:02:39

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 14 July 2026. This shift reflects a complex interplay of deteriorating technical indicators, flat financial performance, and weak long-term fundamentals despite some attractive valuation metrics. The company’s Mojo Score has declined to 44.0, signalling caution for investors amid volatile price action and operational challenges.

Read full news article

Phaarmasia Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials

2026-07-10 08:02:02

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 9 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends despite recent flat quarterly results and ongoing operational challenges.

Read full news article

Phaarmasia Ltd is Rated Sell by MarketsMOJO

2026-07-08 10:11:28

Phaarmasia Ltd is rated Sell by MarketsMOJO, with this rating last updated on 11 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 July 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Phaarmasia Ltd is Rated Sell by MarketsMOJO

2026-06-25 10:11:35

Phaarmasia Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Read full news article

Phaarmasia Ltd Downgraded to Sell Amid Mixed Technicals and Weak Financials

2026-06-12 08:02:03

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a complex interplay of deteriorating technical indicators, flat financial performance, and valuation considerations, despite the company’s impressive long-term returns and attractive price-to-book ratio.

Read full news article

Phaarmasia Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial Signals

2026-06-09 08:04:57

Phaarmasia Ltd has seen its investment rating upgraded from Sell to Hold as of 8 June 2026, reflecting a nuanced shift in its overall outlook. This change is driven by a combination of factors including improved valuation metrics, stable quality indicators, mixed financial trends, and evolving technical signals. Despite recent flat quarterly performance and operational challenges, the stock’s long-term returns and relative valuation have prompted a reassessment of its market stance.

Read full news article

Phaarmasia Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Mixed Returns

2026-06-02 08:01:11

Phaarmasia Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the company’s valuation metrics suggest a more compelling price entry point relative to its historical averages and peer group, warranting a closer examination for investors seeking micro-cap opportunities in Pharmaceuticals & Biotechnology.

Read full news article

Phaarmasia Ltd Q4 FY26: Quarterly Loss Amid Revenue Volatility Raises Sustainability Concerns

2026-05-30 23:47:48

Phaarmasia Limited (NSE: PHAARMASIA, BSE: 523620), a micro-cap pharmaceutical manufacturer specialising in hormonal contraceptive tablets, reported a troubling quarter-on-quarter deterioration in Q4 FY26, posting a net loss of ₹0.70 crores against a profit of ₹16.27 crores in the previous quarter. The Hyderabad-based company, with a modest market capitalisation of ₹53.00 crores, saw its net sales plummet 51.84% sequentially to ₹7.73 crores, raising serious questions about revenue sustainability and operational stability.

Read full news article

Phaarmasia Ltd is Rated Hold by MarketsMOJO

2026-05-29 10:10:42

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. While the rating was revised earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 29 May 2026, providing investors with an up-to-date view of the company’s position in the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News